Tag: MONOGRAPH

  • CB-03-01

    Topical steroidal androgen receptor antagonist with peripherally selective antiandrogen activity

    A synthetic pregnane steroid developed by Cosmo Pharmaceuticals (Cassiopea) as a topically applied, peripherally selective androgen receptor antagonist for the treatment of acne vulgaris and androgenetic alopecia, distinguished from systemic antiandrogens by rapid local metabolism to inactive cortexolone and minimal systemic bioavailability.

    Abstract

    CB-03-01 (clascoterone; cortexolone 17alpha-propionate; 11-deoxycortisol 17alpha-propionate) is a synthetic pregnane steroid that functions as a competitive antagonist of the androgen receptor (AR) with submicromolar potency (IC50 approximately 0.4 to 1 micromolar in AR transactivation assays) and peripheral selectivity conferred by rapid enzymatic hydrolysis to the inactive parent compound cortexolone (11-deoxycortisol) in human skin, plasma, and hepatic tissue. The compound was identified from a structure-activity series of cortexolone 17alpha-monoesters screened for topical antiandrogen activity in the hamster flank organ test, in which CB-03-01 demonstrated potency approximately four times greater than progesterone, three times greater than flutamide, two times greater than finasteride, and approximately equivalent to cyproterone acetate, while lacking systemic antiandrogenic, antianabolic, or glucocorticoid activity after subcutaneous administration in rats. The molecular pharmacology centers on competitive displacement of dihydrotestosterone (DHT) from the androgen receptor in sebocytes and dermal papilla cells, resulting in suppression of androgen-responsive gene transcription, reduction of sebaceous lipid synthesis, inhibition of inflammatory cytokine production (including interleukin-6), and attenuation of androgen-driven miniaturization of scalp hair follicles. In human dermal papilla cell cultures, CB-03-01 demonstrated significantly greater inhibition of DHT-stimulated IL-6 synthesis than the direct AR antagonist enzalutamide.

    The compound received its first regulatory approval from the United States Food and Drug Administration in August 2020 as a 1% topical cream (Winlevi) for the treatment of acne vulgaris in patients aged 12 years and older, representing the first new mechanism of action approved for acne in approximately 40 years and the first topical antiandrogen approved for acne in any jurisdiction. Two pivotal Phase 3 randomized, double-blind, vehicle-controlled trials enrolling a total of 1440 patients with moderate to severe facial acne demonstrated statistically significant treatment success rates (Investigator Global Assessment score of 0 or 1 with at least a two-grade reduction) of approximately 18 to 20 percent for clascoterone versus 7 to 9 percent for vehicle at 12 weeks, with concurrent reductions in both inflammatory and noninflammatory lesion counts. Long-term safety data through 12 months demonstrated a favorable tolerability profile dominated by local application site reactions (erythema, dryness, pruritus) without clinically meaningful systemic antiandrogen effects.

    A second clinical program in androgenetic alopecia (AGA) has advanced through Phase 2 dose-ranging studies (2.5%, 5%, and 7.5% solutions applied twice daily) demonstrating statistically significant improvements in target area hair count (TAHC) at 6 and 12 months, and into Phase 3 registration trials (SCALP-1 and SCALP-2) using a 5% topical solution in 1465 male patients with mild to moderate AGA. The Phase 3 topline results reported statistically significant improvements in TAHC relative to vehicle, with a 5.39-fold relative improvement in one study and a 1.68-fold relative improvement in the second, the divergence attributable to baseline hair count differences rather than inconsistent drug performance. The safety profile in the AGA trials was comparable to vehicle, with no evidence of systemic androgen blockade.

    Pharmacokinetics following topical application are characterized by minimal systemic absorption. The compound is rapidly hydrolyzed in plasma to cortexolone, which is detectable at concentrations generally near or below the lower limit of quantitation (0.5 ng/mL). Plasma protein binding is 84 to 89 percent. The principal safety signal is reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, observed in approximately 7 percent of adolescent and adult subjects in maximal-use pharmacokinetic studies, with all cases resolving within 4 weeks of discontinuation. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mirabegron

    Selective beta-3 adrenergic receptor agonist with secondary CYP2D6 inhibitory activity

    A selective beta-3 adrenoceptor agonist developed by Astellas Pharma as the first non-antimuscarinic oral treatment for overactive bladder, distinguished from the antimuscarinic drug class by its distinct receptor mechanism, favorable dry mouth and cognitive side-effect profile, moderate CYP2D6 inhibitory activity, and emerging research interest in brown adipose tissue thermogenesis, metabolic disease, and oncology.

    Abstract

    Mirabegron (YM-178) is a selective beta-3 adrenergic receptor (beta-3-AR) agonist approved in over 40 countries for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Developed by Astellas Pharma and first approved in Japan in 2011 and by the United States Food and Drug Administration in June 2012, mirabegron represented a paradigm shift in OAB pharmacotherapy as the first non-antimuscarinic agent approved for the indication, offering clinically meaningful efficacy with a substantially lower incidence of the dry mouth, constipation, and cognitive impairment that limit long-term adherence to antimuscarinic agents such as oxybutynin, tolterodine, solifenacin, darifenacin, and fesoterodine. The compound activates beta-3 adrenergic receptors on detrusor smooth muscle cells, producing cyclic adenosine monophosphate (cAMP)-mediated relaxation of the bladder wall during the storage phase and thereby increasing functional bladder capacity without impairing voiding contractility. The compound is also a moderate inhibitor of cytochrome P450 2D6 (CYP2D6), producing clinically relevant increases in systemic exposure to CYP2D6 substrates including metoprolol, desipramine, and thioridazine, a property that requires attention in polypharmacy contexts. The safety profile in pooled clinical trial data and in extensive postmarketing surveillance confirms a low incidence of dry mouth (comparable to placebo), with the principal treatment-emergent adverse events being hypertension (7 to 11 percent), nasopharyngitis, urinary tract infection, and headache. Cardiovascular safety analyses, including a multinational non-interventional cohort study, have not identified increased risk of major adverse cardiovascular events relative to antimuscarinic comparators. Beyond the established OAB indication, mirabegron has attracted substantial research interest as a pharmacological activator of brown adipose tissue (BAT) thermogenesis through beta-3-AR-mediated stimulation of uncoupling protein 1 (UCP1) expression. Chronic mirabegron treatment in human subjects has been shown to increase BAT metabolic activity, resting energy expenditure, high-density lipoprotein cholesterol, adiponectin, and insulin sensitivity, positioning the compound as a research tool for metabolic disease and obesity pharmacology. Additional preclinical research has demonstrated antitumor activity through adipose tissue browning and modulation of the tumor microenvironment. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Vadadustat

    Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) targeting PHD1, PHD2, and PHD3

    An oral 2-oxoglutarate-competitive inhibitor of prolyl-4-hydroxylase domain enzymes developed by Akebia Therapeutics for the treatment of anemia due to chronic kidney disease, distinguished from erythropoiesis-stimulating agents by its mechanism of stabilizing hypoxia-inducible factor to coordinate endogenous erythropoietin production, iron mobilization, and erythroid progenitor maturation.

    Abstract

    Vadadustat (AKB-6548; marketed as Vafseo) is an orally bioavailable small molecule inhibitor of the three human prolyl-4-hydroxylase domain (PHD) isoforms (PHD1, PHD2, PHD3) that regulate the oxygen-sensing hypoxia-inducible factor (HIF) pathway. By competitively displacing the endogenous cofactor 2-oxoglutarate from the PHD active site, vadadustat prevents the hydroxylation and subsequent proteasomal degradation of HIF-alpha subunits, thereby stabilizing HIF-1alpha and HIF-2alpha and activating transcription of erythropoietin, transferrin, transferrin receptor, ferroportin, and other genes that coordinate erythropoiesis and iron homeostasis. The compound was developed by Akebia Therapeutics (Cambridge, Massachusetts) as an alternative to injectable erythropoiesis-stimulating agents (ESAs) for the management of anemia associated with chronic kidney disease (CKD). Vadadustat inhibits all three PHD isoforms with similar low-nanomolar inhibitory constants, and PHD inhibition is competitive with 2-oxoglutarate and insensitive to ambient iron concentration. In preclinical models, a single oral dose in rats potently increased circulating erythropoietin, and daily dosing for 14 days increased red blood cell indices in both healthy rats and the 5/6 nephrectomy model of CKD. In mice and dogs, once-daily repeat oral dosing increased hemoglobin and hematocrit without detectable stimulation of vascular endothelial growth factor.

    The clinical development program comprised the global Phase 3 INNO2VATE trials in dialysis-dependent CKD and the PRO2TECT trials in non-dialysis-dependent CKD, both comparing vadadustat to darbepoetin alfa. In the INNO2VATE program, vadadustat met the prespecified noninferiority criteria for both hematologic efficacy and cardiovascular safety. In the PRO2TECT program, vadadustat met the noninferiority criterion for hematologic efficacy but did not meet the noninferiority criterion for cardiovascular safety, with signals of increased major adverse cardiovascular events (MACE), stroke, and hepatic injury relative to darbepoetin alfa. The United States Food and Drug Administration issued a complete response letter in March 2022 citing cardiovascular and hepatotoxicity concerns. Following review of additional post-marketing safety data from Japan (where Vafseo was approved in 2020) and the clinical trial database, the FDA approved vadadustat in March 2024 for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. The approved labeling carries a boxed warning for increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access, and the compound is explicitly not indicated for non-dialysis CKD patients.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 3 to 4 hours in healthy volunteers, 5 to 6 hours in CKD patients), high plasma protein binding (greater than 99 percent), dose-proportional exposure over a wide dose range, and hepatic glucuronidation as the principal metabolic pathway. The elimination half-life is approximately 4.5 hours in healthy volunteers and extends to 7 to 9 hours in patients with advanced CKD. The compound is a potent inhibitor of the breast cancer resistance protein (BCRP) transporter and a moderate inhibitor of organic anion transporting polypeptide 1B1/1B3 (OATP1B1/1B3), with clinically relevant drug-drug interaction potential for substrates of these transporters. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cariprazine

    Dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist atypical antipsychotic

    A D3-preferring dopamine receptor partial agonist developed by Gedeon Richter as an atypical antipsychotic, distinguished from aripiprazole and brexpiprazole by subnanomolar D3 affinity exceeding that of endogenous dopamine and by the generation of two pharmacologically active long-lived metabolites that collectively produce an effective half-life of approximately one week.

    Abstract

    Cariprazine (RGH-188; marketed as Vraylar) is a dopamine D3-preferring D3/D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist approved by the United States Food and Drug Administration for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder (bipolar depression), and adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant therapy. The compound was discovered by Gedeon Richter Plc. in Budapest, Hungary, first synthesized in 2002, and advanced through clinical development in partnership with Forest Laboratories (subsequently Actavis, Allergan, and AbbVie), receiving initial FDA approval in September 2015 and European Medicines Agency approval in 2017 under the trade name Reagila. Cariprazine is pharmacologically distinguished from the other clinically marketed dopamine partial agonist antipsychotics (aripiprazole, brexpiprazole) by its exceptionally high affinity for the dopamine D3 receptor (Ki approximately 0.085 nM), which exceeds the affinity of endogenous dopamine for the same receptor and produces a degree of D3 occupancy at clinical doses that is not achievable by any other marketed antipsychotic. The D3-preferring profile, with approximately 6- to 8-fold selectivity over D2, is hypothesized to underwrite the compound’s differentiated efficacy on negative symptoms of schizophrenia, cognitive impairment, anhedonia, and motivational deficits, domains that are poorly served by D2-predominant antipsychotic pharmacology. Cariprazine additionally binds the serotonin 5-HT1A receptor as a partial agonist (Ki approximately 2.6 nM) and the serotonin 5-HT2B receptor with high affinity (Ki approximately 0.6 nM), while showing low affinity for histamine H1, muscarinic, and alpha-1 adrenergic receptors, a selectivity profile that predicts low sedation, low anticholinergic burden, and low orthostatic hypotension relative to the broader atypical antipsychotic class.

    The pharmacokinetic profile of cariprazine is dominated by its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), both of which possess pharmacological activity comparable to the parent compound at D3, D2, and 5-HT1A receptors. The parent compound has a half-life of 2 to 4 days; DCAR has a half-life of 1 to 2 days; and DDCAR, the predominant circulating active species at steady state, has a half-life of 1 to 3 weeks. The effective half-life of total active moieties is approximately 1 week, with steady-state equilibrium achieved at approximately 3 weeks of daily dosing. This pharmacokinetic profile has important implications for dose titration (clinical effects may lag dose changes by days to weeks), for drug-drug interactions (strong CYP3A4 inhibitors require dose reduction; strong CYP3A4 inducers are contraindicated), and for washout after discontinuation (pharmacological activity persists for several weeks).

    The clinical evidence base comprises multiple Phase 2 and Phase 3 randomized controlled trials across four approved indications, a head-to-head Phase 3b trial against risperidone for predominant negative symptoms of schizophrenia (demonstrating statistically significant superiority on the PANSS factor score for negative symptoms), and relapse prevention data in schizophrenia. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CE-123

    Atypical selective dopamine transporter inhibitor; modafinil analogue with thiazole bioisosteric replacement

    A benzhydrylsulfinylmethylthiazole developed at the University of Vienna as a next-generation modafinil analogue, distinguished from the parent compound by approximately 30-fold selectivity for the dopamine transporter over the norepinephrine transporter, five-fold superior blood-brain barrier penetration, and a preclinical cognitive enhancement profile spanning memory acquisition, cognitive flexibility, motivation, and social cognition in rodent models of aging, early-life stress, and fetal alcohol spectrum disorders.

    Abstract

    CE-123 (5-((benzhydrylsulfinyl)methyl)thiazole; CAS 1879038-73-9) is a synthetic modafinil analogue and atypical dopamine transporter (DAT) inhibitor developed at the Department of Pharmaceutical Chemistry, University of Vienna, under the direction of Gert Lubec as part of a structure-activity exploration of heterocyclic diphenylmethylsulfinyl derivatives designed to achieve higher selectivity and affinity at the dopamine transporter than the parent compound modafinil. The active enantiomer, (S)-CE-123, inhibits DAT-mediated dopamine reuptake with an EC50 of approximately 2.76 micromolar in HEK293 cells stably expressing human DAT, with approximately 30-fold selectivity over the norepinephrine transporter (NET) and greater than 400-fold selectivity over the serotonin transporter (SERT). The compound interacts with the outward-facing conformation of DAT to block substrate access without triggering reverse transport or vesicular release, a mechanism that defines the atypical DAT inhibitor class and is associated with lower abuse liability than substrate-type releasers such as amphetamine. Pharmacokinetic characterization in Sprague-Dawley rats demonstrates that (S)-CE-123 achieves an unbound brain-to-plasma concentration ratio (Kp,uu,brain) of 0.5, compared to 0.1 for R-modafinil, indicating approximately five-fold superior blood-brain barrier penetration. Hepatic metabolism proceeds via CYP2C19, CYP3A, and CYP2B6, with a 9.3-fold faster hepatic clearance rate compared to modafinil. The principal metabolite (M1) is formed by hydroxylation of one of the aromatic rings.

    The preclinical pharmacology of CE-123 spans multiple cognitive domains tested in several rodent models. In the attentional set-shifting task, CE-123 at 0.3 and 1.0 mg/kg increased cognitive flexibility (reduced extra-dimensional shift errors) without increasing impulsivity. In aged (26-month) Lister Hooded rats, (S)-CE-123 markedly enhanced motivation and performance in a new-to-learn operant discrimination task and in a cooperation assay of social cognition, with post-treatment proteomic analysis of prefrontal cortex synaptosomes revealing modulation of pathways involved in synaptic vesicle recycling, receptor-mediated endocytosis, and alpha-synuclein membrane localization. In a maternal separation model of early-life stress, CE-123 restored spatial memory deficits in adolescent rats with sex-dependent effects favoring females, and normalized maternal-separation-induced upregulation of DAT and dopamine D1 receptor expression in the prefrontal cortex and hippocampus. In a neonatal ethanol exposure model of fetal alcohol spectrum disorders, CE-123 at 3 and 10 mg/kg attenuated locomotor hyperactivity and ameliorated reversal learning impairment. Neurochemical microdialysis studies in freely moving rats demonstrated that (S)-CE-123 at 10 mg/kg intraperitoneally increased extracellular dopamine in the infralimbic/prelimbic cortex with a pharmacodynamic profile distinct from R-modafinil, and produced only a low and transitory dopamine increase in the nucleus accumbens shell, consistent with reduced reinforcing potential.

    No human clinical trials of CE-123 have been published or registered as of the date of this monograph. The compound is not approved by any regulatory authority for human use. It is supplied as a research-grade preparation by multiple chemical vendors at greater than 98 percent purity. A process development and scale-up synthesis has been published (ACS Omega, 2023), establishing a scalable route to the (S)-enantiomer. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • MK-8722

    Direct pan-activator of AMP-activated protein kinase (AMPK) binding the allosteric drug and metabolite (ADaM) site

    A potent, orally bioavailable, direct allosteric pan-AMPK activator developed at Merck Research Laboratories that produces insulin-independent skeletal muscle glucose uptake across species but whose clinical translation was precluded by on-mechanism cardiac hypertrophy and glycogen accumulation in preclinical chronic dosing studies.

    Abstract

    MK-8722 is a potent, direct, orally bioavailable allosteric activator of all twelve mammalian heterotrimeric complexes of AMP-activated protein kinase (AMPK), the master cellular energy sensor that coordinates catabolic and anabolic metabolic pathways in response to energetic stress. Discovered at Merck Research Laboratories through a medicinal chemistry optimization campaign starting from the thienopyridone lead series and published in two landmark reports (Myers et al., Science, 2017; Feng et al., ACS Medicinal Chemistry Letters, 2018), MK-8722 binds the allosteric drug and metabolite (ADaM) site at the interface of the alpha-subunit kinase domain and the beta-subunit carbohydrate-binding module and produces dose-dependent activation of AMPK complexes containing both the beta-1 and beta-2 regulatory subunits.

    The pharmacological consequence of systemic pan-AMPK activation by MK-8722 in preclinical species is a robust, durable, insulin-independent increase in skeletal muscle glucose uptake and glycogen synthesis, with resultant improvements in whole-body glycemia and glucose tolerance in lean and obese rodent models and in spontaneously diabetic rhesus monkeys. The glucose-lowering effect is mediated predominantly through AMPK-dependent translocation of glucose transporter type 4 (GLUT4) to the sarcolemma in skeletal muscle and does not produce hypoglycemia at efficacious doses. Positron emission tomography with [18F]fluorodeoxyglucose ([18F]FDG-PET) confirmed increased skeletal muscle glucose uptake in both rodents and non-human primates following MK-8722 administration. Pharmacokinetic properties in preclinical species supported once-daily oral dosing for chronic studies.

    The principal liability that precluded clinical advancement of MK-8722 was on-mechanism cardiac hypertrophy and cardiac glycogen accumulation observed during chronic dosing in both rodent and non-human primate models. In Sprague-Dawley rats, 4-week oral administration at doses achieving efficacious plasma exposures produced dose-dependent increases in heart weight and left ventricular wall thickness. In rhesus monkeys, 8-week oral administration produced similar cardiac hypertrophy with increased cardiac glycogen content. Echocardiographic assessment demonstrated preserved systolic and diastolic function despite the structural remodeling, and the cardiac hypertrophy appeared partially reversible on drug washout at the highest dose levels, though lower doses did not demonstrate full regression during the studied washout period. No arrhythmias or functional cardiac impairment were detected. The cardiac hypertrophy was attributed to pan-AMPK activation in cardiomyocytes, where AMPK-driven glucose uptake and glycogen synthesis produced pathological glycogen accumulation analogous to the phenotype observed in glycogen storage cardiomyopathy associated with activating mutations in the PRKAG2 gene encoding the AMPK gamma-2 subunit.

    MK-8722 has not entered human clinical trials. The compound remains an important pharmacological tool for the study of systemic AMPK activation in metabolic disease and a reference standard for structure-activity relationship studies in the ADaM-site AMPK activator class. A selectivity screen against 115 enzymes, transporters, and receptors identified modest off-target activity at the serotonin 5-HT2A receptor (Ki approximately 2.8 micromolar) and three additional targets at 3 to 10 micromolar, none of which are anticipated to produce pharmacologically significant effects at AMPK-relevant exposures. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Vesugen

    Synthetic tripeptide bioregulator (Lys-Glu-Asp) targeting vascular endothelial gene expression through epigenetic modulation

    A Khavinson-class synthetic tripeptide bioregulator derived from vascular wall protein sequences, characterized by epigenetic modulation of endothelial proliferation markers, endothelin-1 normalization, sirtuin-1 upregulation, and neuroprotective gene regulation in preclinical aging and Alzheimer’s disease models.

    Abstract

    Vesugen (Lys-Glu-Asp; KED) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson as part of a decades-long program investigating short-chain peptide regulation of age-associated tissue decline. The compound belongs to the Khavinson class of ultrashort (two to four amino acid residue) bioregulatory peptides, a family of synthetic sequences derived from organ-specific protein fractions that are proposed to penetrate cell nuclei and modulate gene expression through direct interactions with DNA promoter regions and epigenetic regulatory mechanisms. Vesugen is the synthetic analog corresponding to the vascular-wall-derived peptide fraction originally isolated as the active component of Ventfort, a polypeptide complex extracted from bovine aortic tissue. The tripeptide sequence Lys-Glu-Asp was identified as the minimal bioactive motif responsible for the vasoprotective activity of the parent extract.

    The molecular pharmacology of Vesugen is characterized by epigenetic modulation of vascular endothelial cell function. In dissociated human endothelial cell cultures, Vesugen stimulates synthesis of the proliferation-associated protein Ki-67, the expression of which declines during cellular aging [1]. Molecular docking studies demonstrate that Vesugen binds to the promoter region of the MKI67 gene, making contact through the CATC sequence at the core promoter located between positions -14 and +12 relative to the transcription initiation site [1]. In models of atherosclerotic and restenotic endothelium in vitro, Vesugen normalizes the expression of endothelin-1, restores connexin (Cx37, Cx43) expression for intercellular communication, and increases sirtuin-1 (SIRT1) expression, implicating the compound in DNA repair and cellular longevity pathways [2, 3]. The compound also modulates expression of vascular endothelial growth factor (VEGF) and the apoptosis marker p53, contributing to a net pro-proliferative and anti-apoptotic phenotype in aged vascular endothelial cells.

    Beyond its primary vascular target, Vesugen has demonstrated neuroprotective activity in several preclinical models. The tripeptide regulates expression of cell aging and apoptosis genes (p16, p21), neuronal differentiation genes and proteins (NES, GAP43, nestin), and genes implicated in Alzheimer’s disease pathogenesis (SUMO, APOE, IGF1) [4]. In hippocampal neuron cultures exposed to amyloid-beta synaptotoxicity, Vesugen increased the number of mushroom-type dendritic spines by 20 percent [5]. Oral administration of Vesugen improved memory and attention in elderly individuals with functional central nervous system disorders in a small clinical cohort [4]. In a 32-patient clinical study of elderly individuals with chronic polymorbidity and organic brain syndrome, Vesugen demonstrated anabolic properties and improved central nervous system activity, slowing the rate of aging as measured by biological age indicators [6].

    The compound is not approved by any national regulatory authority as a pharmaceutical product. It is supplied as a research-grade synthetic peptide and as a dietary supplement (capsule form) in certain jurisdictions. The primary literature on Vesugen originates predominantly from Russian research institutions, principally the Saint Petersburg Institute of Bioregulation and Gerontology and affiliated laboratories. Independent replication by Western laboratories using contemporary structural biology and pharmacology methodologies remains limited. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ulotaront

    Trace amine-associated receptor 1 (TAAR1) full agonist with serotonin 5-HT1A receptor partial agonism

    A first-in-class TAAR1/5-HT1A dual agonist discovered through phenotypic screening, developed for schizophrenia under FDA Breakthrough Therapy Designation, and distinguished from all approved antipsychotics by the absence of dopamine D2 and serotonin 5-HT2A receptor antagonism.

    Abstract

    Ulotaront (SEP-363856) is a thienopyran-based small molecule and the first trace amine-associated receptor 1 (TAAR1) agonist to reach Phase 3 clinical development for the treatment of schizophrenia. Discovered through a target-agnostic phenotypic screening collaboration between PsychoGenics and Sunovion Pharmaceuticals (now Sumitomo Pharma), ulotaront was identified using the SmartCube automated behavioral platform rather than rational design against TAAR1, and its molecular target was subsequently deconvoluted to reveal full agonism at human TAAR1 (EC50 approximately 38 to 140 nM, Emax approximately 101 to 109 percent) and partial agonism at the serotonin 5-HT1A receptor (EC50 approximately 2.3 micromolar, Emax approximately 75 percent). The compound is not an antagonist at either the dopamine D2 or the serotonin 5-HT2A receptor, the two canonical targets of all currently approved first-generation and second-generation antipsychotics. This mechanistic distinction positions ulotaront as a fundamentally novel pharmacological approach to psychotic disorders, with a preclinical and early clinical profile that suggests potential advantages in the avoidance of extrapyramidal symptoms, metabolic syndrome, hyperprolactinemia, and sedation that limit the tolerability of existing antipsychotic therapies.

    The compound prevented olanzapine-induced weight gain in rodents and demonstrated no effect on prolactin release. Pharmacokinetics are characterized by rapid oral absorption, greater than 70 percent bioavailability in preclinical species, high blood-brain barrier penetration (brain concentrations approximately threefold higher than plasma), a median effective half-life of approximately 7 hours in humans supporting once-daily dosing, and predominant hepatic metabolism through CYP2D6. The compound received FDA Breakthrough Therapy Designation in May 2019 on the basis of a positive Phase 2 randomized controlled trial (Koblan et al., 2020) in 245 acutely psychotic adults with schizophrenia, in which ulotaront at 50 to 75 mg/day produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score of 17.2 points versus 9.7 points on placebo at four weeks (effect size 0.45, p less than 0.001), with concurrent improvement on negative symptom, depressive symptom, and global severity measures. A 26-week open-label extension demonstrated sustained improvement (PANSS total reduction of 41.8 points from double-blind baseline) with a favorable metabolic and movement disorder safety profile.

    The Phase 3 DIAMOND program, however, produced negative results. DIAMOND 1 (ulotaront 50 and 75 mg/day versus placebo in 435 patients) and DIAMOND 2 (ulotaront 75 and 100 mg/day versus placebo in 464 patients) both failed to meet their primary endpoints at six weeks, with large placebo responses potentially masking the therapeutic signal. Additional Phase 3 studies (DIAMOND 3, long-term extension, and a switch study versus quetiapine) were planned or ongoing at the time of the negative readouts. Despite the Phase 3 setback in schizophrenia, ulotaront continues in Phase 2/3 development for generalized anxiety disorder and as adjunctive therapy in major depressive disorder, reflecting the broader neuropsychiatric potential of the TAAR1 mechanism. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Chlodantane

    Adamantane-derived actoprotector and synthetic adaptogen with membrane-stabilizing, antioxidant, and immunostimulant activity

    An adamantane-derived para-chlorobenzamide developed at the Zakusov State Institute of Pharmacology as a rapid-onset synthetic adaptogen, distinguished from bromantane by a benzoyl (rather than amine) linkage, broader adaptogenic activity spectrum, and more pronounced immunostimulant properties in preclinical models.

    Abstract

    Chlodantane (ADK-910), the para-chlorobenzoyl amide of 2-aminoadamantane, is an experimental actoprotector and synthetic adaptogen developed at the Zakusov State Institute of Pharmacology of the Russian Academy of Medical Sciences during an extensive structure-activity campaign that screened 329 novel adamantane derivatives for resistance-enhancing properties in rodent stress models [1, 2]. The compound emerged alongside bromantane (N-(2-adamantyl)-N-(para-bromophenyl)amine) as one of two lead adamantane-derived actoprotectors from the Morozov laboratory program; however, whereas bromantane proceeded to clinical registration in Russia as Ladasten for the treatment of neurasthenia, chlodantane was never advanced to human studies and remains an exclusively preclinical research compound.

    Structurally, chlodantane differs from bromantane in the nature of the bond connecting the adamantane cage to the halogenated aromatic ring. Bromantane is a secondary amine (N-(2-adamantyl)-N-(4-bromophenyl)amine), whereas chlodantane is an amide (N-(2-adamantyl)-4-chlorobenzamide), a distinction that alters conformational flexibility, hydrogen-bonding capacity, metabolic susceptibility, and physicochemical behavior [1]. The chlorine-for-bromine halogen substitution is a secondary modification.

    The mechanism of action has not been fully elucidated. The available evidence, derived entirely from animal and cell-culture experiments, points to membrane stabilization as a principal contributor. Chlodantane increases the stability of cell membranes against unfavorable conditions, achieved in part through suppression of overactivated lipid peroxidation (LPO) processes [2, 3]. The adamantane cage, a rigid tricyclo[3.3.1.1(3,7)]decane skeleton with high lipophilicity, partitions into lipid bilayers and interacts with the polar headgroup region of phospholipid membranes, a property shared across the broader adamantane pharmacological class and formally characterized in molecular dynamics simulations of amantadine and memantine in model bilayers [4, 5]. The immunostimulant activity of chlodantane is reported to be more pronounced than that of bromantane, with efficacy in secondary stress-induced immunodeficiency models, though the molecular targets mediating this effect have not been identified [1, 2].

    No human pharmacokinetic, efficacy, or safety data exist for chlodantane. The pharmacokinetic profile is inferred from the structurally related bromantane, which displays moderate oral bioavailability (approximately 42 percent), a plasma elimination half-life of approximately 11 hours, hepatic hydroxylation of the adamantane ring as the principal metabolic pathway, and wide tissue distribution driven by the lipophilicity of the adamantane core [6, 7]. Whether the amide bond in chlodantane introduces additional metabolic liabilities (amide hydrolysis, different ring-hydroxylation regioselectivity) relative to the amine bond in bromantane has not been characterized. The compound is not approved for medical use in any jurisdiction and is not listed on any national pharmacopoeia. It is available as a research-grade preparation from limited specialty chemical suppliers at purities stated as greater than 98 percent. Investigators should obtain independent analytical confirmation of identity, purity, and stereochemical composition on every lot. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Nortadalafil

    Synthetic phosphodiesterase type 5 (PDE5) inhibitor; N-desmethyl analogue of tadalafil

    An unapproved, demethylated structural analogue of tadalafil with retained nanomolar PDE5 inhibitory potency, identified principally as a synthetic adulterant in dietary supplements marketed for sexual enhancement and as a reference standard for forensic and analytical chemistry.

    Abstract

    Nortadalafil (demethyl tadalafil, CAS 171596-36-4) is a synthetic analogue of the clinically approved phosphodiesterase type 5 (PDE5) inhibitor tadalafil, distinguished from the parent compound by the absence of the N-methyl substituent on the piperazinedione ring of the hexahydropyrazinopyridoindole scaffold. The compound retains nanomolar inhibitory potency against PDE5 (IC50 approximately 11 to 12 nM against bovine PDE5, compared to approximately 5 nM for tadalafil) and produces cGMP-mediated smooth muscle relaxation with EC50 values of 300 to 600 nM in rat aortic preparations. Despite this pharmacological activity, nortadalafil has never been submitted for regulatory approval in any jurisdiction and has not been the subject of controlled clinical trials in human subjects. The compound first entered the scientific literature through its detection as an undeclared adulterant in herbal and dietary supplements marketed for erectile dysfunction, a context in which it represents one member of a large and expanding family of synthetic PDE5 inhibitor analogues (including aminotadalafil, N-octylnortadalafil, chloropretadalafil, and others) introduced into the unregulated supplement market to evade analytical screening for the approved parent compounds. Analytical characterization of nortadalafil in adulterated products relies on high-performance liquid chromatography with diode-array and mass spectrometric detection, high-resolution mass spectrometry, and nuclear magnetic resonance spectroscopy. No systematic toxicology, no formal pharmacokinetic characterization in healthy volunteers under regulatory oversight, and no controlled efficacy data exist for the compound. Safety concerns are inferred from the PDE5 inhibitor class and include the absolute contraindication of concurrent nitrate administration (risk of severe, potentially fatal hypotension), the interaction with alpha-adrenergic receptor antagonists and potent CYP3A4 inhibitors, and the unknown dose-response and adverse-event profile of a compound consumed without medical supervision at uncharacterized doses in adulterated supplements. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.